Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials.

abstract：:Anorexia nervosa (AN), bulimia nervosa (BN) and binge eating disorder (BED) each occur in about 0.5-1.5% of the population in westernised countries, and primarily affect women. At present, a variety of pharmacological treatments are used in addition to psychotherapy, with antidepressants being most the common. Current...

journal_title：Expert opinion on investigational drugs

authors： Crow S

更新日期：1997-04-01 00:00:00

abstract：INTRODUCTION:There has been a striking increase in the emergence of multidrug-resistant pathogens in recent times. Delafloxacin is a novel, broad-spectrum fluoroquinolone with antimicrobial activity against resistant Gram-positive, Gram-negative and anaerobic organisms. It has the potential to treat a variety of infect...

journal_title：Expert opinion on investigational drugs

authors： Bassetti M,Della Siega P,Pecori D,Scarparo C,Righi E

更新日期：2015-03-01 00:00:00

abstract：INTRODUCTION:IL-6 is a key cytokine in the pathogenesis of rheumatoid arthritis (RA). The clinical efficacy of tocilizumab (TCZ), a humanized anti-IL6-receptor mAb, confirmed the value of IL-6 blockade in this disease. A number of new anti-IL-6 biologics are currently in Phase I - III of clinical development for RA. A...

journal_title：Expert opinion on investigational drugs

authors： Semerano L,Thiolat A,Minichiello E,Clavel G,Bessis N,Boissier MC

更新日期：2014-07-01 00:00:00

abstract：:There is a growing understanding of the central role that platelets play in coronary artery disease. The glycoprotein IIb/IIIa receptor has recently been identified as the final common pathway for platelet aggregation and hence has been the focus of many clinical trials to influence various aspects of coronary artery ...

journal_title：Expert opinion on investigational drugs

authors： Salam AM,Suwaidi JA

更新日期：2002-11-01 00:00:00

abstract：:Growth hormone-insensitivity syndrome (GHIS) is usually caused by mutations in the growth hormone receptor. Recombinant IGF-I has been used to treat GHIS either alone (mecasermin) or in combination with IGF-binding protein (IGFBP)-3 (mecasermin rinfabate). IGF-I increases the growth velocity of children with IGF defic...

journal_title：Expert opinion on investigational drugs

authors： Kemp SF,Thrailkill KM

更新日期：2006-04-01 00:00:00

abstract：:Thienopyridines have a well-established role in the treatment of coronary artery disease, especially in the setting of acute coronary syndromes and percutaneous coronary interventions. Ticlopidine, the first FDA-approved thienopyridine, was shown to be effective in reducing coronary events in high risk patients, but t...

journal_title：Expert opinion on investigational drugs

authors： Porto I,Giubilato S,De Maria GL,Biasucci LM,Crea F

更新日期：2009-09-01 00:00:00

abstract：:Recently there have been considerable advances made in the treatment of multiple sclerosis. For the first time since its initial clinical description in the 1800s, there are now available several medications which unequivocally exert favourable clinical effects through the lowering of the biological activity of the hu...

journal_title：Expert opinion on investigational drugs

authors： Goodin DS

更新日期：2000-04-01 00:00:00

abstract：:PTI-821 is a long-acting formulation of oxycodone that is intended to deter abuse through its gel-cap technology. Produced by Pain Therapeutics in alliance with King Pharmaceuticals, PTI-821 is designed to provide strong pain relief with the intent of offering greater safety than is presently available from convention...

journal_title：Expert opinion on investigational drugs

authors： Webster LR

更新日期：2007-03-01 00:00:00

abstract：:Liver targeted therapy is designed to deliver a substance preferentially to the organ in order to increase the accumulation, improve the therapeutic effect and reduce toxicity to other organs. The aim of selective targeting is to deliver a substance to a specific cell type in the liver. A variety of vehicles have been...

journal_title：Expert opinion on investigational drugs

authors： Wu J,Wu GY,Zern MA

更新日期：1998-11-01 00:00:00

abstract：INTRODUCTION:The N-methyl-d-aspartate receptor-ionophore complex plays a key role in learning and memory and has efficacy in animals and humans with affective disorders. GLYX-13 is an N-methyl-d-aspartate receptor (NMDAR) glycine-site functional partial agonist and cognitive enhancer that also shows rapid antidepressan...

journal_title：Expert opinion on investigational drugs

authors： Moskal JR,Burch R,Burgdorf JS,Kroes RA,Stanton PK,Disterhoft JF,Leander JD

更新日期：2014-02-01 00:00:00

abstract：:Introduction: Renal cell carcinoma (RCC) consists of distinct clinical and biologic entities, with an urgent need for novel therapies targeting histology-specific molecular drivers of cancer growth. The MET pathway is now being targeted by multiple novel agents in clinical development. This review highlights the upcom...

journal_title：Expert opinion on investigational drugs

authors： Nandagopal L,Sonpavde GP,Agarwal N

更新日期：2019-10-01 00:00:00

abstract：INTRODUCTION:Heat shock proteins (Hsps) are part of a complex network of chaperone proteins that are critically involved in the conformational maturation of intracellular proteins and regulate their degradation via the proteasome system Hsps (especially Hsp70 and Hsp90) are upregulated in many cancers and are potential...

journal_title：Expert opinion on investigational drugs

authors： Subramaniam DS,Warner EA,Giaccone G

更新日期：2017-01-01 00:00:00

abstract：:The deposition of a platelet rich thrombus on an atherosclerotic plaque is a critical step in the development of unstable coronary syndromes. Currently available therapeutic agents such as aspirin and ticlopidine are relatively weak inhibitors of platelet aggregation. Recently, antagonists to platelet glycoprotein IIb...

journal_title：Expert opinion on investigational drugs

authors： Kumar A,Herrmann HC

更新日期：1997-09-01 00:00:00

abstract：INTRODUCTION:Basal-like breast cancer is characterized by being triple negative and aggressive. Defects in DNA repair is a promising therapeutic target as BRCA alterations are found in 11 to 42% of these tumors, with a frequency varying according to family history and ethnicity. The oral PARP inhibitors exploit this de...

journal_title：Expert opinion on investigational drugs

authors： Robert M,Frenel JS,Gourmelon C,Patsouris A,Augereau P,Campone M

更新日期：2017-06-01 00:00:00

abstract：:This perspective is the second in a series discussing drugs dropped from development in 2006, with a focus on pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs. A survey of discontinued drugs from 2006 is provided, based on data from the Pharmaprojects database, along with an analysis of biology,...

journal_title：Expert opinion on investigational drugs

authors： Ozdemir C,Akdis CA

更新日期：2007-09-01 00:00:00

abstract：:Several lines of evidence suggest that chronic heart failure is a state of chronic inflammation. Indeed, various pro-inflammatory markers, including the cytokines TNF-alpha, and interleukin 6 and 1, are activated in the course of the disease. In chronic heart failure, these substances are frequently induced even befor...

journal_title：Expert opinion on investigational drugs

authors： von Haehling S,Anker SD

更新日期：2005-02-01 00:00:00

abstract：:Preclinical studies suggest that the brain corticotropin-releasing factor (CRF) systems mediate anxiety-like behavioural and somatic responses through actions at the CRF1 receptor. CRF1 antagonists block the anxiogenic-like effects of CRF and stress in animal models. Cerebrospinal fluid levels of CRF are elevated in s...

journal_title：Expert opinion on investigational drugs

authors： Zorrilla EP,Koob GF

更新日期：2004-07-01 00:00:00

abstract：:All of the glucose-lowering agents available today for the treatment of diabetes resulted from the in vivo antidiabetic drug discovery approach. This is not surprising given the limited understanding of the biochemical basis of diabetes. With new developments in the elucidation of the biochemistry and physiology of di...

journal_title：Expert opinion on investigational drugs

authors： Luo J

更新日期：1998-06-01 00:00:00

abstract：:High-density lipoprotein (HDL) therapy is a novel and emerging area of therapeutic development in the cardiovascular field. It attempts to supplement and improve the vascular benefit exerted by other agents that are active on lipid metabolism, for example, hypolipidaemic drugs. Furthermore, it takes advantage of the n...

journal_title：Expert opinion on investigational drugs

authors： Marchesi M,Sirtori CR

更新日期：2006-03-01 00:00:00

abstract：BACKGROUND:Based partially on encouraging findings from preclinical models, interest has grown in therapeutic inhibition of NF-kappaB to limit inflammatory injury during sepsis. However, NF-kappaB also regulates protective responses, and predicting the net survival effects of such inhibition may be difficult. OBJECTIV...

journal_title：Expert opinion on investigational drugs

authors： Li X,Su J,Cui X,Li Y,Barochia A,Eichacker PQ

更新日期：2009-08-01 00:00:00

abstract：INTRODUCTION:The current standard treatment in persons with hemophilia (PWH) is prophylaxis, given intravenously twice or thrice weekly, which is associated with a non negligible burden on patients' quality of life. Therefore the main attempts aiming to improve the management of PWH are targeted towards the development...

journal_title：Expert opinion on investigational drugs

authors： Mannucci PM,Mancuso ME

更新日期：2013-08-01 00:00:00

abstract：:Restenosis, the re-narrowing of the lumen of the coronary artery, in the months following a successful percutaneous balloon angioplasty or stenting, remains the main limitation to percutaneous coronary revascularisation. Serial intravascular ultrasound studies have shown that restenosis after conventional balloon angi...

journal_title：Expert opinion on investigational drugs

authors： Gruberg L,Waksman R,Satler LF,Pichard AD,Kent KM

更新日期：2000-11-01 00:00:00

abstract：INTRODUCTION:Compounds that inhibit or modulate γ-secretase, the pivotal enzyme which generates β-amyloid (Aβ), are potential therapeutics for Alzheimer's disease (AD). AREAS COVERED:This article briefly reviews the profile of γ-secretase inhibitors that have reached the clinic and discusses the clinical issues surrou...

journal_title：Expert opinion on investigational drugs

authors： Imbimbo BP,Panza F,Frisardi V,Solfrizzi V,D'Onofrio G,Logroscino G,Seripa D,Pilotto A

更新日期：2011-03-01 00:00:00

abstract：:Neuroimmunophilin ligands are a class of compounds that hold great promise for the treatment of nerve injuries and neurological disease. In contrast to neurotrophins (e.g., nerve growth factor), these compounds readily cross the blood-brain barrier, being orally effective in a variety of animal models of ischaemia, tr...

journal_title：Expert opinion on investigational drugs

authors： Gold BG

更新日期：2000-10-01 00:00:00

abstract：INTRODUCTION:Gut-specific homing is mainly mediated by the expression of MAdCAM-1 on endothelial cells. An increase in MAdCAM-1 expression has been shown in patients with inflammatory bowel disease (IBD). Areas covered: PF-00547659 is a fully human monoclonal antibody (mAb) toward MAdCAM-1 on endothelial cells, blockin...

journal_title：Expert opinion on investigational drugs

authors： Allocca M,Gilardi D,Fiorino G,Furfaro F,Argollo M,Peyrin-Biroulet L,Danese S

更新日期：2018-07-01 00:00:00

abstract：:AGI-1067 is a derivative of probucol that is a promising new development for the treatment of restenosis and possibly atherosclerosis. In monkeys fed a high-fat diet for 1 year, AGI-1067 prevented the development of atherosclerosis. In these monkeys, AGI-1067 lowered plasma levels of low-density lipoprotein (LDL)-chol...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2003-11-01 00:00:00

abstract：INTRODUCTION:Tetomilast is a novel thiazole phosphodiesterase-4 (PDE-4) inhibitor, which may prove useful in both the treatment of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD). Here, the authors review the pharmacology of the drug, and offer critical review of the available data for...

journal_title：Expert opinion on investigational drugs

authors： Bickston SJ,Snider KR,Kappus MR

更新日期：2012-12-01 00:00:00

abstract：:Many peptides are synthesised and released from the gastrointestinal tract. Although their roles in the regulation of gastrointestinal function have been known for some time, it has become increasingly evident that they also influence eating behaviour. Peptide YY (PYY) is released postprandially from gastrointestinal ...

journal_title：Expert opinion on investigational drugs

authors： Small CJ,Bloom SR

更新日期：2005-05-01 00:00:00

abstract：:Despite the use of the statins to lower low-density lipoprotein-cholesterol, leading to major reductions in the mortality and morbidity that is associated with coronary artery disease, considerable mortality and morbidity remains. Increasing high-density lipoprotein (HDL)-cholesterol levels has been associated with re...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2006-02-01 00:00:00

abstract：:Standard drug therapy of adult polymyositis, dermatomyositis and inclusion body myositis includes high-dose corticosteroids and cytotoxic drugs (methotrexate, azathioprine (AZA) and cyclophosphamide). Recent data are in favour of the early introduction of a cytotoxic or immunomodulating drug in addition to corticoster...

journal_title：Expert opinion on investigational drugs

authors： Fam AG

更新日期：2001-07-01 00:00:00